[HTML][HTML] Glycogen synthase kinase-3 signaling in Alzheimer's disease

E Lauretti, O Dincer, D Praticò - … et Biophysica Acta (BBA)-Molecular Cell …, 2020 - Elsevier
Alzheimer's disease (AD) is the most common form of neurodegenerative disorder with
dementia, accounting for approximately 70% of the all cases. Currently, 5.8 million people in …

GSK-3 and Tau: a key duet in Alzheimer's disease

CL Sayas, J Ávila - Cells, 2021 - mdpi.com
Glycogen synthase kinase-3 (GSK-3) is a ubiquitously expressed serine/threonine kinase
with a plethora of substrates. As a modulator of several cellular processes, GSK-3 has a …

GSK-3β, a pivotal kinase in Alzheimer disease

M Llorens-Marítin, J Jurado, F Hernández… - Frontiers in molecular …, 2014 - frontiersin.org
Alzheimer disease (AD) is the most common form of age-related dementia. The etiology of
AD is considered to be multifactorial as only a negligible percentage of cases have a familial …

Neuroinflammation and neurogenesis in Alzheimer's disease and potential therapeutic approaches

PS Sung, PY Lin, CH Liu, HC Su, KJ Tsai - International journal of …, 2020 - mdpi.com
In adult brain, new neurons are generated throughout adulthood in the subventricular zone
and the dentate gyrus; this process is commonly known as adult neurogenesis. The …

Parkinson's disease, aging and adult neurogenesis: Wnt/β‐catenin signalling as the key to unlock the mystery of endogenous brain repair

B Marchetti, C Tirolo, F L'Episcopo, S Caniglia… - Aging cell, 2020 - Wiley Online Library
A common hallmark of age‐dependent neurodegenerative diseases is an impairment of
adult neurogenesis. Wingless‐type mouse mammary tumor virus integration site (Wnt)/β …

GSK3 and tau: two convergence points in Alzheimer's disease

F Hernandez, JJ Lucas, J Avila - Journal of Alzheimer's …, 2012 - journals.sagepub.com
Glycogen synthase kinase 3 (GSK3) is a ubiquitously expressed serine/threonine kinase
that plays a key role in the pathogenesis of Alzheimer's disease (AD). GSK3 phosphorylates …

[HTML][HTML] PROTACs technology for treatment of Alzheimer's disease: Advances and perspectives

H Inuzuka, J Liu, W Wei, AH Rezaeian - Acta materia medica, 2022 - ncbi.nlm.nih.gov
Neurodegenerative diseases (NDs) are characteristic with progression of neuron
degeneration, resulting in dysfunction of cognition and mobility. Many neurodegenerative …

Alzheimer's disease, enzyme targets and drug discovery struggles: from natural products to drug prototypes

T Silva, J Reis, J Teixeira, F Borges - Ageing research reviews, 2014 - Elsevier
Alzheimer's disease (AD) is an incapacitating neurodegenerative disease that slowly
destroys brain cells. This disease progressively compromises both memory and cognition …

[HTML][HTML] Recent advances in PROTACs for drug targeted protein research

T Yao, H Xiao, H Wang, X Xu - International Journal of Molecular …, 2022 - mdpi.com
Proteolysis-targeting chimera (PROTAC) is a heterobifunctional molecule. Typically,
PROTAC consists of two terminals which are the ligand of the protein of interest (POI) and …

The role of dopamine signaling in epileptogenesis

Y Bozzi, E Borrelli - Frontiers in cellular neuroscience, 2013 - frontiersin.org
Clinical and experimental studies implicate most neuromodulatory systems in
epileptogenesis. The dopaminergic system has a seizure-modulating effect that crucially …